Autopsy report · NCT00910000

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

“Terminated due to unacceptable toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 years 4 months before it stopped.
• 15 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer

Interventions

Vorinostat; Carboplatin; Gemcitabine

Participants

15

Sites

2

Countries

United States

Trials that died the same way

• A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
  “Terminated due to dose limiting toxicity” (85% match in meaning)
• GSK2983559 First Time in Human Study
  “Terminated due to non clinical toxicology findings and reduced safety margins.” (83% match in meaning)
• Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
  “Terminated due to lack of efficacy” (80% match in meaning)
• Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
  “Terminated due to safety concerns.” (78% match in meaning)
• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.